aTyr Pharma Inc - Company Profile
Powered by 
All the data and insights you need on aTyr Pharma Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date aTyr Pharma Inc Strategy Report
- Understand aTyr Pharma Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
ATyr Pharma Inc (ATyr Pharma) is a clinical-stage biotechnology company. It includes in discovery and clinical development of medicines for the treatment of cancer and lung diseases. The company's ATYR1923 is a clinical-stage product candidate based on the resokine pathway which binds to the neuropilin-2 receptor harnesses immune engagement in interstitial lung diseases and other immune-mediated diseases. It also concentrates on research and development of the extracellular functionality of tRNA synthetases. ATyr Pharma also develops drugs for cancer, inflammation, neurodegenerative diseases and metabolic disorders. The company collaborates with research institutions for its research and development activities. ATyr Pharma is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
10240 Sorrento Valley Road, Suite 300, San Diego, California, 92121
Website
www.atyrpharma.com
Telephone
1 858 7318389
No of Employees
56
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LIFE (NASD)
Revenue (2022)
$353,000
-96.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-11.1%
(2022 vs 2021)
Market Cap*
$108.7M
Net Profit Margin (2022)
XYZ
-3,170.0%
(2022 vs 2021)
* As of and is in US$
aTyr Pharma Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Efzofitimod - Pulmonary Sarcoidosis |
| ATYR0101 - Fibrosis |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | aTyr Pharma Inc | Mirum Pharmaceuticals Inc | MEI Pharma Inc | Lumos Pharma Inc | Albireo Pharma Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Diego | Foster City | San Diego | Austin | Boston |
| State/Province | California | California | California | Texas | Massachusetts |
| No. of Employees | 56 | 264 | 46 | 33 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John K. Clarke | Chairman | Executive Board | 2005 | 69 |
| Sanjay S. Shukla, M.D. | Director; President; Chief Executive Officer | Executive Board | 2017 | 51 |
| Jill Broadfoot | Chief Financial Officer | Senior Management | 2018 | 61 |
| Nancy E. Denyes | Corporate Secretary; General Counsel | Senior Management | 2019 | 55 |
| Leslie Nangle | Vice President - Research | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer